Hana Safah, MD
Hematology & Oncology · Baton Rouge, LANPI 1447344783
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,630,350 of the $2,037,969 with a category attached, or 80.0%. 57 manufacturers reported payments, led by Incyte Corporation at 31.0% of the total. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,920 payments — averaging $1061.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$632K
- Blueprint Medicines Corporation$207K
- Astellas Pharma US Inc$158K
- Johnson & Johnson$137K
- GSK$136K
- Jazz Pharmaceuticals Inc.$127K
- plus $641K from 51 others
Across 208 payments — averaging $8563.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$470K
- Pharmaessentia USA Corporation$447K
- Pfizer$410K
- Bristol Myers Squibb$140K
- E.r. Squibb & Sons, L.L.C.$68K
- AstraZeneca$64K
- plus $182K from 9 others
What the payments were for
- Consulting fees$144,4477%
- Speaking & faculty fees$1,630,35080%
- Travel & lodging$230,00611%
- Food & beverage$32,9532%
- Education$2130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,037,969 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 16 | $187 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Baton Rouge
- Nakhle SabaBaton Rouge$842K
- Sanjay JunejaBaton Rouge$346K
- Andrew DalovisioBaton Rouge$128K
- Greg BizetteBaton Rouge$32K
- Marshall StaggBaton Rouge$19K
- Christopher McCanlessBaton Rouge$18K
- Georgios ConstantinouBaton Rouge$15K
- Lauren JunejaBaton Rouge$14K
- Victor LinBaton Rouge$10K
- Pedro BarataNew Orleans$928K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.